Abstract
The transforming growth factor β (TGFβ) pathway exhibits pro-tumorigenic effects across multiple malignancies via its impact on tumor cells, microenvironment, and/or the immune system.1,2 Therefore, there is a growing impetus to target the TGFβ signaling axis across malignancies.1,2 Although early-phase/dose-defining trials with TGFβR1 (ALK5) inhibitor in glioma3 and TGFβ2 oligo therapy in anaplastic astrocytoma4 have shown improved outcomes, albeit in a small subset of patients, the molecular determinants that dictate response to TGFβ-pathway targeted therapies, however, remain elusive; underscoring a broader unmet need in precision oncology.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
